scholarly journals Hubungan antara Faktor Klinikohistopatologi dan Kualitas Hidup Pasien Kanker Endometrium Pasca Operasi di RSUP Dr.Sardjito Yogyakarta Menggunakan Modul Kuesioner EORTC QLQ-C30 dan EN 24

2021 ◽  
Vol 8 (1) ◽  
pp. 23
Author(s):  
Dini Mahrani ◽  
Ahsanudin Attamimi ◽  
Ardhanu Kusumanto
Keyword(s):  
Quality Of Life ◽  
Cancer Research ◽  
Endometrial Cancer ◽  
Therapeutic Success ◽  
Cross Sectional ◽  
Clinical Patient ◽  
The World ◽  
C 30 ◽  
Eortc Qlq

Background: According to data from the "Endometrial Cancer Report" by the World Cancer Research Fund and the American Institute for Cancer Research (WCRFI), endometrial cancer is the sixth most common malignancy in the world and is the largest cancer in female organs, after cervical cancer. This incidence is increasing every year, it is predicted to increase about 5% of new cases each year. The main prognostic factors of endometrial cancer are determined by the histological type, stage, degree, differentiation of the tumor, invasive myometrial level and increase in lympho-vascular invasion. In addition to determining the histopathological factors, the prognosis is also determined from the clinical patient. Several studies have shown certain clinical factors also improve the condition and prognosis of the disease. Prognosis of this disease with the quality of life of patients becomes an interesting topic to discuss. Besides that quality of life is also a measure of therapeutic success. The better the prognosis of a disease, the better the quality of life, the higher the success rate of therapy (Greimel, 2010).Objective: To know correlation between clinicohistopathological and quality of life in patients with endometrial cancer after undergoing surgery at Sardjito Hospital, Yogyakarta.Method: The research is analytic with cross sectional approach. Patients with endometrial cancer who have undergone total hysterectomy and bisalpingoophorectomy surgery are assessed for their quality of life through interviews and filling out questionnaires in the EORTC QLQ-C 30 and QLQ-EN 24 modules.Results and Discussion: This study, most people with endometrial cancer aged 55-65 years were 34 people (42%) and diagnosed after menopause with a range of age >55 years as many as 43 people (53.1%). This study cannot prove the hypothesis that age, parity, body mass index, type of histopathology and KGB involvement have a relationship with the quality of life of cancer patients (p >0.05). But in contrast to the stage of early cancer (OR 3.17, p=0.044 (CI 95% 1.03-9.75)) and good and moderate differentiation (OR 4.471, p=0.023 (CI 95% 1.23-16.24)) have a significant relationship with quality of life.Conclusion: Clinicohistopathological factors (cancer stage and tumor differentiation) have a correlation with the quality of life at patients with postoperative endometrial cancer in  Sardjito Hospital Keywords: Endometrial cancer; clinicohistopathological factors; quality of life

scholarly journals Quality of life among ovarian cancer survivors in Haji Adam Malik General Hospital Medan, Indonesia

2020 ◽  
Vol 11 (2) ◽  
pp. 133-139
Author(s):  
Kristivani Br Ginting ◽  
Muhammad Rizki Yaznil ◽  
M. Oky Prabudi ◽  
Lili Rahmawati
Keyword(s):  
Quality Of Life ◽  
Ovarian Cancer ◽  
Cancer Survivors ◽  
General Hospital ◽  
Detection Methods ◽  
Cross Sectional ◽  
Eortc Qlq C30 ◽  
C 30 ◽  
Eortc Qlq

Latar belakang: Kanker ovarium memiliki angka mortalitas yang cukup tinggi dikarenakan gejalanya yang tidak spesifik, sering ditemukan pada stadium lanjut, dan belum adanya metode deteksi dini yang sudah terbukti. Untuk menilai keberhasilan terapi penyintas kanker ovarium, tidak hanya dinilai dari aspek klinis tetapi juga dinilai dari kualitas hidup penyintas kanker ovarium yang penilaiannya berdasarkan skala fungsional dan skala gejala dalam kuesioner EORTC QLQ C30 dan EORTC QLQ OV28. Metode: Penelitian ini menggunakan desain penelitian cross sectional, menggunakan data primer dari hasil wawancara dengan kuesioner EORTC QLQ C30 dan EORTC QLQ OV28 serta data sekunder yang berasal dari rekam medik di RSUP Haji Adam Malik Medan tahun 2017 - 2018. Sampel penelitian dipilih dengan metode total sampling dari seluruh data rekam medik yang memenuhi kriteria penelitian.   Hasil: Hasil penelitian ini didapatkan kualitas hidup global penyintas kanker ovarium 89.36% adalah baik, dan 10.64% adalah sedang serta tidak ada yang memiliki kualitas hidup buruk. Namun, didapatkan adanya gangguan pada skala fungsional berupa: fungsi emosional, fungsi kognitif, fungsi seksual, dan sikap terhadap penyakit, serta adanya permasalahan pada skala gejala berupa: kelelahan, nyeri, neuropati perifer, dan gejala menopause. Didapatkan juga tidak ada hubungan karakteristik usia, jenis histopatologis, stadium, lama terapi dengan kualitas hidup penyintas kanker ovarium, namun terdapat hubungan antara jenis terapi dengan kualitas hidup penyintas kanker ovarium. Kesimpulan: Kualitas hidup penyintas kanker ovarium secara global adalah baik. Kata Kunci: Kualitas Hidup, Penyintas Kanker Ovarium, EORTC QLQ C-30, EORTC QLQ     OV-28   Abstract Background: Ovarian cancer has a high mortality rate due to nonspecific symptoms, often found at an advanced stage, and also the absence of proven early detection methods. To assess the success of ovarian cancer survivors therapy, it is not only assessed from the clinical aspect but also from the quality of life of ovarian cancer survivors which is based on the functional and symptom scale in the EORTC QLQ C30 and EORTC QLQ OV28 questionnaires.  Methods: This study used a cross-sectional study design, using primary data from interviews with the survivors based on the questionnaire EORTC QLQ C30 and EORTC QLQ OV28 as well as secondary data derived from medical records at Haji Adam Malik General Hospital Medan in 2017 - 2018. The research sample was used with a total sampling method from all medical record data that fulfill the research criteria.  Result: The quality of life of ovarian cancer survivors is generally good (89.36%), meanwhile the rest is moderate (10.64%) without the poor quality of life. However, there are disorders on the functional scale in the form of emotional function, cognitive function, sexual function, and attitude toward disease. Likewise on the scale of symptoms, there are problems including: fatigue, pain, peripheral neuropathy, and menopausal symptoms.  Conclusion: The quality of life of ovarian cancer survivors globally is good. Keywords: Quality of Life, Ovarian Cancer Survivors, EORTC QLQ C-30, EORTC QLQ OV-28  

scholarly journals Chronic Lymphocytic Leukemia (CLL) Patients Quality of Life (QoL): A Cross-Sectional Analysis of the Italian Experience in the Choice Study during the First Wave of the COVID-19 Pandemic

Blood ◽  
2021 ◽  
Vol 138 (Supplement 1) ◽  
pp. 4680-4680
Author(s):  
Alessandra Tedeschi ◽  
Idanna Innocenti ◽  
Francesco Albano ◽  
Alessandro Gozzetti ◽  
Luciano Levato ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Treated Group ◽  
Concomitant Treatment ◽  
Future Health ◽  
Cross Sectional ◽  
Patient Reported ◽  
C 30 ◽  
Eortc Qlq ◽  
The Impact

Abstract Introduction Although plenty of data exists on efficacy and safety of CLL drugs, their impact on patients' Health-Related Quality of Life (HRQoL) is largely unknown (1-2). Documentation of drug safety via traditional use of adverse events (AE) in hematology is limited if not complemented with Patient-Reported Outcomes (PRO) measures (3-4). Incorporation of HRQoL PROs is now essential to better evaluate risk-benefit of new therapeutic approaches and it is also highly valued by regulatory stakeholders (5). Most PRO data currently available for CLL patients (pts) came from randomized controlled trial settings (6-7), hence limiting generalizability of findings to CLL real-life patients. CHOICE study was designed to investigate CLL patients' QoL and preference towards different treatment profiles through a Discrete Choice Experiment (DCE) methodology in Italy. Due to the timelines of the study, which started in February 2020, the related data offer an insight into patients' perception and worries during the first wave of the COVID-19 pandemic. Methods This cross sectional, multi-center, observational study included CLL patients, treatment naïve during the watch & wait period (W&W) or already TREATED (around 50% each, controlled at site level), who signed the informed consent for study participation. Exclusion criteria were inability to take oral drugs, cognitive disorders that could impair the comprehension of the questionnaires and concomitant treatment for other malignancies. Patients were asked to fill in the following HRQoL questionnaires: EQ-5D-5L, EORTC QLQ-C30 and QLQ CLL-16, as well as a DCE questionnaire, (described elsewhere). Each questionnaire was completed by the patient on a tablet - using an App specifically developed for the study. Results 401 pts were enrolled in Italy in 16 hematology centers (Feb - July 2020); 199 W&W and 196 TREATED pts completed the questionnaires and were included in the evaluable population. Main patients' characteristics are shown in Table 1. 73.7% of TREATED pts were ON-treatment (30.8% were in 1st-line, 69,2% in further lines) and 26.3% were OFF-treatment; the majority of pts (55,6%) were currently treated with a target therapy (Table1). The EQ-5D-5L questionnaire showed no significant differences between groups. In both groups more than 80% of pts reported low values (1 or 2, indicating no or small impact) on all items. Median VAS was 75 for the TREATED group and 80 for the W&W group (0-100; higher scores indicate higher QoL). QLQ C-30 / CLL-16 scores had very similar results between TREATED and W&W pts suggesting a limited impact of CLL on pts QoL. The median (IQR) QoL Scale was 83.3 (67- 83) for TREATED and 83.3 (67- 92) for W&W pts (0-100; all functional scales had high scores, that represent a better level of functioning; all symptoms' scales had low values, representing a less important symptomatology or problem, Figure 1). The main symptoms reported were fatigue, insomnia, pain, and dyspnea, while the main worry was for "future health" (Figure 1). Distribution of data was statistically different between the 2 groups only for the Role functioning Scale (p=0.024) and the Social Functioning Scale (p=0.003) of QLQ-C30 and for the Infection Scale (p<0.001) of QLQ CLL-16, always with slightly but significantly better results for the W&W group. Conclusions CHOICE study helps to understand the CLL patients' mindset and feeling in the light of the COVID-19 pandemic impact on health care for this category of pts, highlighting their preferences and worries in a large cohort of pts in Italy, allowing a comparison between TREATED and W&W pts. The main limitation of the study was its cross-sectional design, which does not allow us to evaluate any change in QoL neither with respect to the impact of the pandemic, nor to the effects of the treatment, if any. CLL pts showed a good QoL, as confirmed by both EQ-5D-5L and EORTC QLQ C-30 / CLL-16 scores, with very similar results between TREATED and W&W pts (although slightly better results in the W&W vs TREATED group). The results of the present study are consistent with previous reports, and fatigue was the most reported symptom, while worry for future health was the most relevant score in CLL-16 questionnaire. Hospital accesses reduction that was detected during the pandemic might have influenced patients' response, as well as the extreme attention towards the danger of infections, and might have impacted patients' perception on future health. Figure 1 Figure 1. Disclosures Tedeschi: Beigene: Honoraria, Speakers Bureau; AstraZeneca: Honoraria, Speakers Bureau; AbbVie: Honoraria, Speakers Bureau; Janssen: Honoraria, Speakers Bureau. Gozzetti: Janssen: Honoraria; AbbVie: Honoraria. Reda: Beigene: Consultancy; Astra Zeneca: Consultancy; Abbvie: Consultancy; Janssen: Consultancy. Gualberti: AbbVie: Current Employment. Malgieri: AbbVie: Current Employment. Finsinger: AbbVie: Current Employment.

scholarly journals Psychometric validation of the Moroccan version of the EORTC QLQ-C30 in colorectal Cancer patients: cross-sectional study and systematic literature review

BMC Cancer ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Yacir El Alami ◽  
Hajar Essangri ◽  
Mohammed Anass Majbar ◽  
Saber Boutayeb ◽  
Said Benamr ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Colorectal Cancer ◽  
Discriminant Validity ◽  
Cross Sectional Study ◽  
Cross Sectional ◽  
Related Quality ◽  
Eortc Qlq C30 ◽  
Eortc Qlq ◽  
Colorectal Cancer Patients

Abstract Background Health-related quality of life is mainly impacted by colorectal cancer which justified the major importance addressed to the development and validation of assessment questionnaires. We aimed to assess the validity and reliability of the Moroccan Arabic Dialectal version of the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Core Questionnaire (QLQ-C30) in patients with colorectal cancer. Methods We conducted a cross-sectional study using the Moroccan version of the EORTC QLQ-C30 on colorectal cancer patients from the National Oncology Institute of Rabat, in the period from February 2015 to June 2017. The QLQ-C30 was administered to 120 patients. Statistical analysis included reliability, convergent, and discriminant validity as well as known-groups comparisons. Results In total, 120 patients with colorectal cancer were included in the study with 38 (32%) patients diagnosed with colon cancers. Eighty-two patients (68%) had rectal cancer, among which 29 (24%) patients with a stoma. The mean age of diagnosis was 54 years (+/− 13.3). The reliability and validity of the Arabic dialectal Moroccan version of the EORTC QLQ-C30 were satisfactory. [Cronbach’s alpha (α =0.74)]. All items accomplished the criteria for convergent and discriminant validity except for question number 5, which did not complete the minimum required correlation with its own scale (physical functioning). Patients with rectal cancer presented with bad Global health status and quality of life (GHS/QOL), emotional functioning as well as higher fatigue symptoms compared to patients with colon cancer. The difference between patients with and without stoma was significant for diarrhea and financial difficulty. Conclusions The Moroccan Arabic Dialectal version of the QLQ-C30 is a valid and reliable measure of health-related quality of life (HRQOL) in patients with colorectal cancer.

ENGOT-en11/GOG-3053/KEYNOTE-B21: Phase 3 study of pembrolizumab or placebo in combination with adjuvant chemotherapy with/without radiotherapy in patients with newly diagnosed high-risk endometrial cancer.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. TPS5608-TPS5608
Author(s):  
Toon Van Gorp ◽  
Mansoor Raza Mirza ◽  
Alain Lortholary ◽  
David Cibula ◽  
Axel Walther ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Endometrial Cancer ◽  
High Risk ◽  
Adjuvant Chemotherapy ◽  
Combination Therapy ◽  
Stage I ◽  
Newly Diagnosed ◽  
Phase 3 ◽  
Eortc Qlq

TPS5608 Background: Pembrolizumab, a selective humanized anti–PD-1 monoclonal antibody, has demonstrated activity in patients with previously treated mismatch repair (MMR) deficient (dMMR; 57.1% ORR as monotherapy and 63.6% ORR as combination therapy with lenvatinib) and MMR proficient (pMMR; 36.2% ORR as combination therapy with lenvatinib) endometrial cancer (EC). ENGOT-en11/GOG-3053/KEYNOTE-B21 is a phase 3, randomized, double-blind study of pembrolizumab or placebo in combination with adjuvant chemotherapy with/without radiotherapy in patients with EC. Methods: Eligible patients are ≥18 years old with newly diagnosed, histologically confirmed high-risk (stage I/II non-endometrioid, stage III/IVa, p53 abnormality) EC (carcinoma or carcinosarcoma) following surgery with curative intent with no evidence of disease post-operatively or on imaging, and without prior systemic therapy/radiotherapy. In total, ̃990 patients are randomized to receive pembrolizumab 200 mg or placebo Q3W for 6 cycles + chemotherapy (carboplatin area under the curve [AUC] 5 or 6 + paclitaxel 175 mg/m2 Q3W or carboplatin AUC 2 or 2.7 + paclitaxel 60 mg/m2 QW) in stage 1. Patients receive pembrolizumab 400 mg or placebo Q6W for 6 cycles in stage 2 per their treatment assignment. At the investigator’s discretion, radiotherapy (external beam radiotherapy [EBRT] and/or brachytherapy) ± radiosensitizing cisplatin 50 mg/m2 (days 1 and 29) may be administered after completion of chemotherapy. Randomization is stratified by MMR status (pMMR vs dMMR) and, within pMMR, by planned radiation therapy (cisplatin-EBRT vs EBRT vs no EBRT), histology (endometrioid vs non-endometrioid), and International Federation of Gynecology and Obstetrics (FIGO) surgical stage (I/II vs III/IVA). Dual primary endpoints are disease-free survival (DFS; per investigator assessment) and overall survival (OS), both estimated by the Kaplan-Meier method, with a stratified log-rank test to assess treatment differences and a Cox proportional hazard model with Efron’s method of tie handling to assess the magnitude of treatment differences. Secondary endpoints include DFS (per blinded independent central review), DFS (per investigator assessment) and OS by biomarker status (PD-L1 and tumor mutational burden), safety (per National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0) and quality of life (per European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 [EORTC QLQ-C30] and Endometrial Cancer Module [EORTC QLQ-EN24]). The study began enrollment in December 2020. Clinical trial information: NCT04634877.

scholarly journals Longitudinal Associations of Adherence to the World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR) Lifestyle Recommendations with Quality of Life and Symptoms in Colorectal Cancer Survivors up to 24 Months Post-Treatment

Cancers ◽  
2022 ◽  
Vol 14 (2) ◽  
pp. 417
Author(s):  
Marlou-Floor Kenkhuis ◽  
Floortje Mols ◽  
Eline H. van Roekel ◽  
José J. L. Breedveld-Peters ◽  
Stéphanie O. Breukink ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Colorectal Cancer ◽  
Cancer Research ◽  
Post Treatment ◽  
Research Fund ◽  
American Institute ◽  
The World ◽  
Lifestyle Recommendations ◽  
Longitudinal Associations

Post-treatment adherence to the World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR) lifestyle recommendations were associated with health-related quality of life (HRQoL), fatigue, and chemotherapy-induced peripheral neuropathy (CIPN) in colorectal cancer (CRC) survivors. In a prospective cohort among CRC survivors (n = 459), repeated home-visits were performed at 6 weeks, 6, 12, and 24 months post-treatment. Dietary intake, body composition, sedentary behaviour, and physical activity were assessed to construct a lifestyle score based on adherence to seven 2018 WCRF/AICR recommendations. Longitudinal associations of the lifestyle score with HRQoL, fatigue, and CIPN were analysed by confounder-adjusted linear mixed models. A higher lifestyle score was associated with better physical functioning and less activity-related fatigue, but not with CIPN. Adjustment for physical activity substantially attenuated observed associations, indicating its importance in the lifestyle score with regards to HRQoL. In contrast, adjustment for body composition and alcohol inflated observed associations, indicating that both recommendations had a counteractive influence within the lifestyle score. Our findings suggest that CRC survivors benefit from an overall adherence to the WCRF/AICR lifestyle recommendations in terms of HRQoL and fatigue, but not CIPN. Specific recommendations have a varying influence on these associations, complicating the interpretation and requiring further study.

Predicting the Quality of Life in Patients with Gastrointestinal Cancers in Iranian Population

2016 ◽  
Vol 9 (1) ◽  
pp. 43
Author(s):  
Aliakbar Hajaghamohammadi ◽  
Somayeh Ahmadi Gooraji ◽  
Ali Zargar
Keyword(s):  
Quality Of Life ◽  
Gastric Cancer ◽  
Cancer Patients ◽  
Study Data ◽  
Cross Sectional ◽  
Social And Emotional ◽  
Gi Cancers ◽  
Eortc Qlq ◽  
Gastric Cancer Patients

BACKGROUND: Evaluation of the quality of life (QoL) of cancer patients gives valuable information regarding the burden of disease, type of treatment and its side effects in studies on chronic diseases. In this study an attempt is made to predict the QoL of patients with gastrointestinal (GI) cancer.METHODS: In a cross sectional prospective study, data of 107 patients with GI cancers 58 male & 49 female with a mean age of 60.7±10.5 referred to a hospital from April 2009 to June 2015 were collected by using two standard questionnaires of EORTC-QLQ C30 and EORTC-QLQ-GINET 21. Data analysis was done using multivariate analysis of variance (MANOVA) and correlation test in soft wares of STATA and SPSS.16.RESULTS: Total QoL score was 50.7±24.6 in patients with gastrointestinal cancer which is almost optimal. Symptoms level was more in gastric cancer patients and their major complaints were constipation and diarrhea.  QoL of patients with GI cancers were more affected by the educational level and type of cancer (P<0.05).A high correlation of QoL was related to social and emotional domains (P<0.05). Mean score of QoL was more in males with colorectal cancer, educated and retired patients (P<0.05).CONCLUSION: the social and emotional support to patients with esophageal cancer and to reduce the level of symptoms in patients with gastric cancer due to complications of their diseases or treatment should be of consideration to improve their QoL.

Health-related quality of life of of women with breast cancer undergoing chemotherapy in the northern region of Brazil.

2015 ◽  
Vol 33 (28_suppl) ◽  
pp. 92-92
Author(s):  
Namie Okino Sawada ◽  
Mary Elizabeth de Santana ◽  
Helena Megumi Sonobe
Keyword(s):  
Breast Cancer ◽  
Quality Of Life ◽  
Rural Areas ◽  
Health Related Quality ◽  
European Organization ◽  
Related Quality ◽  
Health Related ◽  
C 30 ◽  
Eortc Qlq

92 Background: In Brazil, the estimate for the year 2015 is approximately 576,000 new cases of cancer. Breast cancer is the most common in Brazilian women and the state of Pará is the first with the highest incidence of breast cancer in northern Brazil. The high incidence and changes caused by treatment and own illness as the disturbances in body image, functional, emotional and social changes cause fear in women, as well as disrupting daily activities and impact the health-Related Quality of Life (HRQOL). Improving HRQOL is an important goal so the evaluation of HRQoL of these patients is of interest to health professionals, as they provide information that help in planning treatment and rehabilitation. The objective is to evaluate the HRQoL of patients with breast cancer in chemotherapy treatment. Methods: It is a cross-sectional study with quantitative exploratory design. This place was a public hospital in the city of Belém do Pará, Women were included with breast cancer, over eighteen years old and excluded those with cognitive problems and metastases. The European Organization for Research and Treatment of Cancer Quality of Life (EORTC QLQ C 30) and Questionnaire Breast Cancer Module (QLQ BR23) have been administrated. The project was approved by the Ethics Committee and were respected the resolution 466/2012 CNS / MS. Results: The sample consisted of 89 women with breast cancer undergoing chemotherapy, most in the age group over 40, mulatto, married, fundamental level of education, domestic load, Catholic religion, live in rural areas with incomes of one to two minimum salaries. The EORTC QLQ C 30 showed that the average QOL was 75.56, and the most impaired functions were physical (M = 65.62) and role performance (M = 58.61) and the most frequent symptoms were diarrhea, constipation, dyspnea, nausea and vomiting, fatigue, pain and loss of appetite. EORTC BR23 demonstrated functional scale (M = 49.95) and symptoms scale (M = 33.00). Conclusions: The results show that the side effects of chemotherapy affect the physical and functional function and consequently HRQoL of these patients.

Comparative quality of life in patients randomized contemporaneously to docetaxel or abiraterone in the STAMPEDE trial.

2020 ◽  
Vol 38 (6_suppl) ◽  
pp. 14-14 ◽  
Author(s):  
Hannah L. Rush ◽  
Adrian David Cook ◽  
Christopher D. Brawley ◽  
Laura Murphy ◽  
Archie Macnair ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Repeated Measures ◽  
Treatment Options ◽  
Locally Advanced ◽  
Standard Of Care ◽  
Clinical Parameter ◽  
Cross Sectional ◽  
Multi Stage ◽  
Eortc Qlq

14 Background: Docetaxel (DOC) and abiraterone (ABI) both improve overall survival (OS) in men with locally advanced or metastatic hormone-sensitive prostate cancer (HSPC) but no head to head trials compare the 2 agents. STAMPEDE, a multi-arm multi-stage platform trial, recruited patients (pts) to treatments including DOC or ABI between Nov-11 and Mar-13. There was no evidence OS differed between DOC or ABI, thus quality of life (QOL) may increasingly inform treatment options. Methods: QOL scores were analysed in pts contemporaneously randomised to receive DOC or ABI, in addition to standard of care treatment. Self-assessment QOL questionnaires EORTC QLQ C30 and PR25 were completed during treatment and follow-up. These analyses focus on average global QOL over the first 2 years after randomisation, using repeated measures analysis, plus cross-sectional analyses at 3, 6, 12 and 24 months. A score difference of ≥4 points was pre-defined as clinically meaningful. Results: 173 men randomised to DOC and 342 men randomised to ABI participated in the QOL sub-study and contributed to this analysis. Baseline characteristics and proportion of missing data were similar between groups. Baseline global QOL scores were similar (mean (sd): DOC 77.8 (20) and ABI 78.0 (19.3)). Average global QOL over 2 years was higher in pts randomised to ABI than DOC, although the difference was statistically significant it did not meet the pre-defined clinical parameter (+3.9, 95%CI 0.6 to 7.1, p=0.021). Cross-sectional analyses showed clinically meaningful superior QOL in the ABI group at 3 and 6 months (+6.6, 95%CI 2.6 to 10.7, p=0.001; +8.0, 95%CI 3.6 to 12.3, p<0.001), but not at 1 or 2 years (+1.3, 95%CI -3.0 to 5.6, p=0.545; +4.5, 95%CI -0.25 to 9.2, p=0.063). An exploratory analysis indicated average QOL for pts with metastatic disease (n=207) was better in the ABI group (+4.44, 95%CI 0.2 to 8.6, p=0.036). Conclusion: Global QOL was significantly higher in the first 2 years of treatment for the ABI group compared to the DOC group, though did not meet the pre-defined clinically meaningful threshold. The majority of difference was seen in the first year of treatment. This should be considered when discussing treatment options with pts. Clinical trial information: NCT00268476.

scholarly journals Cancer in the Adolescent and Young Adults (AYA) and Children: A Comprehensive Analysis of the Epidemiology and Psychosocial Morbidity in the Indian Population

2021 ◽  
Author(s):  
Bhupesh Guleria ◽  
S. Viswanath ◽  
Dharmesh Soneji ◽  
Rajan Kapoor ◽  
Prerna Guleria ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Young Adults ◽  
Life Questionnaire ◽  
Solid Organ ◽  
Children With Cancer ◽  
Adolescent And Young Adults ◽  
C 30 ◽  
Eortc Qlq ◽  
Psychosocial Morbidity

Aims Adolescent and young adults (AYAs), children with cancer, and their guardians have unique psychosocial morbidities adversely effecting quality of life (QOL). This is measurable using patented tools. We analyzed epidemiological and clinicopathological patterns of solid organ cancers in this subgroup. We also assessed psychosocial morbidity and changes in QOL faced by them. Methods All patients aged 2 to 39 years, newly diagnosed with cancer from April 2017 to March 2019 were included. Clinical history, diagnosis, staging, treatment, outcomes, and follow-up were recorded. The National Comprehensive Cancer Network (NCCN) distress thermometer and European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ C-30) were used to assess psychosocial morbidity of AYAs, children ≥ 12 years, and parents of children < 12 years. Pediatric Quality of Life Inventory (Peds QL) version 3.0 was used for children < 12 years. Data was analyzed using descriptive statistics. Results A total of 571 patients (512 AYAs, 59 children) were enrolled. Median age was 30 years with male predominance (58.1%). Most cases (98.6%) were absent from school or work. Carcinoma breast was the most common in females (29.3%) and non-Hodgkin lymphoma in males (12.6%). 91.06% had overall NCCN distress score ≥ 4. Also, 73.81 and 79.49% had “quite a bit” or “very much” responses on functional and symptom scales, respectively, in EORTC QLQ C-30 questionnaire. Peds QL version 3.0 revealed total score ranging from 276 to 523 for each patient. Conclusion AYAs and children with cancer are extremely vulnerable to psychological stress and morbidity. Use of well-established tools help in assessing their mental status and timely psychiatric referral can be initiated.

scholarly journals Reconstructive Surgery in Soft Tissue Sarcomas—Long-Term Outcome and Quality of Life

2017 ◽  
Vol 102 (11-12) ◽  
pp. 480-488
Author(s):  
Reiner Wirbel ◽  
Steffen Weber ◽  
Angela Olinger ◽  
Wolf Mutschler ◽  
Tim Pohlemann
Keyword(s):  
Quality Of Life ◽  
Functional Outcome ◽  
Reconstructive Surgery ◽  
Soft Tissue Sarcomas ◽  
Tumor Stage ◽  
Stage Ii ◽  
C 30 ◽  
Eortc Qlq

The long-term oncological and functional outcome including quality of life should be evaluated in soft tissue sarcomas (STS). The need for reconstructive surgery with possible influence on the results should also be analyzed. Tumor stage mainly influences the prognosis of STS. Advances in reconstructive surgery mostly allow limb salvage. Limited information exists about functional outcome and life quality. A total of 86 patients (51 men, 35 women, mean age 50.5 years) with a minimum follow-up of 10 years were analyzed. We determined the oncological outcome (local recurrences, metastases, overall survival) of tumors at varying stages: stage I (n = 30), stage II (n = 52), and stage III (n = 4). Functional outcome and quality of life of the survivors were measured using the Musculoskeletal Tumor Society (MSTS) criteria and the EORTC-QLQ-C-30 (European Organisation for Research and Treatment of Cancer-Quality of Life-Questionnaire-Core-30 module) questionnaire. Tumor stage influenced the survival and the development of metastases. Survival rates were 89.5 and 88% after 5 and 10 years in stage I, and 56.5 and 49% in stage II tumors. Surgical margin influenced the development of local recurrence. Reconstructive procedures were necessary in 27 patients. After a median follow-up of 144 months, 36 patients were dead: 29 of their malignancy and 7 of other diseases. Fifty long-term survivors presented good results for MSTS (mean score: 82.4) and EORTC-QLQ-C-30 (mean score: 79.8), the results were independent on the need of reconstructive surgery. In stage II STS, the survival drops even after 5 years. The surgical treatment of STS requires the knowledge of different reconstructive techniques; functional results and quality of life are not compromised by the need for reconstructive surgery.

Sign in / Sign up

Export Citation Format

Share Document